Pavel Vasilevich Apanovich

Pavel Vasilevich Apanovich

Auto-generated profile, based on publicly available information

Pavel Vasilevich Apanovich

Research Centre for Medical Genetics

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2011 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
TNTatyana Vasilevna Nikonova
Tatyana Vasilevna Nikonova
PAPavel Vasilevich Apanovich
Pavel Vasilevich Apanovich
EPElena Vladimirovna Pekareva
Elena Vladimirovna Pekareva
VGVera Anatolevna Gorelysheva
Vera Anatolevna Gorelysheva
SSSvetlana Mikhaylovna Stepanova
Svetlana Mikhaylovna Stepanova
AKAleksandr Vasilevich Karpukhin
Aleksandr Vasilevich Karpukhin
Latent autoimmune diabetes of adults (LADA) is a variant of autoimmune diabetes mellitus. Its clinical feature not typical for classical DM1 despitethe presence of positive autoantibodies is characterized by the low rate of autoimmune destruction that accounts for the late development of insulindependence. Similar to classical DM1, LADA is associated with the loss of immune tolerance to autoantibodies. However, the quantitative andfunctional activity of Treg as key regulators of the immune response and main agents of immune tolerance remain as poorly known as their relationshipwith characteristics of apoptosis.Aim. To elucidate qualitative and functional changes at the level of immunity regulation in patients with LADA of different duration and theirrelationships with characteristics of apoptosis, immunological and genetic markers. Materials and methods. The study included 64 patients (45 men and 19 women) with LADA and 56 control subjects. The methods included HLAgenotyping, detection of autoantibodies against GAD, insulin, tyrosine phosphatase, islet cell antigens, composition of CD3+, CD4+, CD38+, HLADR+, CD25+, CD+25+, CD95, CD95L lymphocyte subpopulations, FoxP3 and C-peptide expression, HbA1c levels. Results. FoxP3 expression at the onset of LADA was similar to that in control subjects while the relative amount of CD425+high T-lymphocytes increased.In contrast to DM1, FoxP3 expression began to decrease 6-12 months after the onset of LADA when the amount of CD425+high T-lymphocytes loweredto become normal with the progress of the disease. Within 1-5 years after the onset of LADA, FoxP3 expression became normal again but significantlyincreased when its duration exceeded 5 years. Expression of apoptosis markers (CD95 and CD95L) on lymphocytes and of their soluble forms in allLADA patients was comparable with control. Conclusion. We for the first time determined intensity of FoxP3 expression and the amount of CD425+high T-lymphocytes in patients with differentduration of LADA. FoxP3 expression varies periodically while functional deficit of Treg is delayed and appears to be compensated by a rise in theirnumber. Increased population of Treg within 6 months after the onset of LADA may reflect their regulatory role (suppression of autoimmunity)accounting for the gradual development of the disease.

11 December 2018 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
FKFatimat Kipkeeva
Fatimat Kipkeeva
ТMТ. А. Muzaffarova
Т. А. Muzaffarova
MNMaxim Petrovich Nikulin
Maxim Petrovich Nikulin
PAP. V. Apanovich
P. V. Apanovich
SNS. N. Nered
S. N. Nered
AKAlexander Karpukhin
Alexander Karpukhin
Objective of the study. Identification of genes, the expression of which is associated with the metastasis of gastric cancer tumor.Materials and methods. Quantitative real-time PCR on paired tumor – normal samples.Results. An association with the metastasis of the VEGFR1, FGFR2 and NRP-1 gene expression is shown. The odds ratio (OR) was the highest for the FGFR2 gene: OR 175.00; 95 % CI 8.972–3413.271; for the VEGFR1 gene, OR 4.622, 95 % CI 1.240–17.227, for NRP1 – OR 2.667; 95 % CI 0.597–11.915. When assessing the jointly elevated expression of VEGFR1 and NRP1 genes, OR 5,778; 95 % CI 1.393–23.909; p = 0.0147. The frequency of increased expression of FGFR2 was 5 % in case of metastasis, while in the case of localized GC it reached 53 %.Conclusion. The target drug against FGFR2, which is being developed, is likely to have a limited 5–10 % frequency of effective action in metastatic GC. Its use in the early stages of GC can help prevent the transition of the tumor to the metastatic stage. The possible interact tion of VEGFR1 and NRP1 will result in a small contribution to the metastasis of GC as compared to the effect of VEGFR1-only expression.

1 April 2022 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
NANatalya Apanovich
Natalya Apanovich
PAP. V. Apanovich
P. V. Apanovich
DMDanzan Mansorunov
Danzan Mansorunov
AKAnna Kuzevanova
Anna Kuzevanova
AKAlexandra Korotaeva
Alexandra Korotaeva
AKAlexander Karpukhin
Alexander Karpukhin

28 August 2018 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
FKFatimat Kipkeeva
Fatimat Kipkeeva
ТМТатьяна Александровна Музаффарова
Татьяна Александровна Музаффарова
MNMaxim Petrovich Nikulin
Maxim Petrovich Nikulin
ПАПавел Васильевич Апанович
Павел Васильевич Апанович
AKAlexander Karpukhin
Alexander Karpukhin
Understanding the molecular genetic features of gastric cancer (GC) and principally the functioning of signaling cascades involved in its occurrence and development is determining for identifying the most promising genes for targeted therapy. On this basis, development and consequent implementation of effective drugs and treatment regimens is conducted. The inductors of signaling paths, the main one of which is the mTOR pathway, and the functioning of the pathway are considered in details. mTOR inductors (angiogenesis factors, epidermal growth factor and their receptors) are most actively studied as therapeutic targets. Particular attention is paid to the consideration of stimulation and development of lymphangiogenesis where not all genes are discovered and examined yet. The possibility of achieving a significant therapeutic effect with simultaneous inhibition of the action of genes of angio- and lymphangiogenesis is considered. The review covers the administered target drugs and pharmaceuticals under investigation for GC therapy, including immunotherapy. The review provides details on the simultaneous activation of several genes ― potential targets of therapy and possible interactions in the development of the tumor process. As a result the combined effect of the simultaneous action of two or more factors can be detected. The possibility of maintaining the activated signaling cascade when one of the activated receptors is blocked in consequence of the action of another expressed receptor is also considered. The article presents information on development of drugs affecting several targets and on effectiveness of combined therapy with different targeted drugs. Essential effectiveness of GC therapy can be achieved by personified treatment including application of molecular classification. The review discusses the prognostic value of target and other genes expression, as well as GC subtypes according molecular classification.

10 December 2021 in Cancer Urology
Verified
Journal Article
Open access
PDF file
NANatalya Apanovich
Natalya Apanovich
AMA. V. Matveev
A. V. Matveev
PAP. V. Apanovich
P. V. Apanovich
AKAlexandra Korotaeva
Alexandra Korotaeva
FKFatimat Kipkeeva
Fatimat Kipkeeva
AKAlexander Karpukhin
Alexander Karpukhin
Background. Metastasing and degree of differentiation refer to the main clinical characteristics of malignant tumors. Both listed features need an in-depth study that can lead to an understanding of the mechanisms for the occurrence of certain state of cancer cells.Objective. Studying the processes of metastasis and differentiation of the clear cell renal cell carcinoma (ccRCC) on gene expression.Materials and methods. The levels of expression of ten genes in 65 paired samples were studied (ccRCC tumor tissue and the normal kidney tissue) by the real-time polymerase chain reaction.Results. It is shown that the expression of CA9, NDUFA4L2, VWF, IGFBP3, BHLHE41, ANGPTL4 and EGLN3 genes is associated both with the degree of differentiation of the ccRCC and with the metastasis of this tumor. C1QA expression is connected only with metastasis, but does not participate in the process of differentiation of tumor cells. An ambiguous situation with FN1 and CSF1R gene expression is not essential for ccRCC metastasis processes, but may have a certain value for differentiation of cells of this tumor. Low-differentiated tumors have about five times an increased metastasis frequency during the year relative to highly differentiated tumors (odds ratio 4.94). A low correlation of gene expression in tumors with a low degree of differentiation is revealed, as opposed to their high co-expression during tumor progression by TNM classifications.Conclusion. A significant part of genes substantial for the development of ccRCC is associated with both metastasis and the degree of differentiation of the ccRCC, which is due to the similarity of functional changes that stimulate both of these processes. For low-differentiated tumors the number of genes with correlated expression is less than in high-differentiated tumors. This may be due to disorganization of gene expression.